3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-2-oxo-4-(trifluoromethyl)-3H-indole-6-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-2-oxo-4-(trifluoromethyl)-3H-indole-6-carboxamide
• 化学式: C₂₂H₂₃ClF₃N₃O₂
• 分子量: 453.9
• InChiKey: GABSEFBZIPLXHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• OCULAR DRUG DELIVERY SYSTEM
  申请人：Jade Therapeutics, LLC

  公开号：EP2838511B1

  公开（公告）日：2018-05-30
• [EN] OCULAR DRUG DELIVERY SYSTEM<br/>[FR] SYSTÈME D'ADMINISTRATION DE MÉDICAMENT OCULAIRE
  申请人：JADE THERAPEUTICS LLC

  公开号：WO2013158661A1

  公开（公告）日：2013-10-24

  An ocular drug delivery system including a composition in which a formulation having an active agent (e.g., HGH, rHGH or an HGH mimic) that increases insulin growth factor (IGF) or that alters insulin growth factor binding protein (IGFBP) in a subject is dispersed in a pharmaceutical carrier. The composition is configured for placement in, around or on an eye of the subject, and the composition provides controlled release of an amount of the active agent to the eye effective to promote ocular surface and corneal neural regeneration and wound healing.